A stronger team
We are pleased to announce that we have hired Jesper Kjerulff, starting on June 1st, to serve as the project leader for the continued development of our candidate compound PN6047 and lead the project into phase 1 clinical trials in Q2 2022.
Jesper has a high level of strategic proficiency and business acumen with a solid background from Lundbeck as a senior project manager. His experience spans 18 years of project management roles in the context of small molecules and biologics, and he has a proven track record in interactions with authorities in the EU, US, Japan, and China.
For 11 years, Jesper served as global project lead for the successful development of Brintellix® from preclinical development through the I, II and III phases, and on to registration and launch. Before that, he managed several other well-known projects through all phases. Jesper is also known for his excellence in stakeholder communications and is a member of consultancy group KLIFO.
With Jesper on board, our team now has all the skills required for the journey ahead. We are convinced that Jesper will make a strong contribution to the success of PN6047
A stronger team
We are pleased to announce that we have hired Jesper Kjerulff, starting on June 1st, to serve as the project leader for the continued development of our candidate compound PN6047 and lead the project into phase 1 clinical trials in Q2 2022.
Jesper has a high level of strategic proficiency and business acumen with a solid background from Lundbeck as a senior project manager. His experience spans 18 years of project management roles in the context of small molecules and biologics, and he has a proven track record in interactions with authorities in the EU, US, Japan, and China.
For 11 years, Jesper served as global project lead for the successful development of Brintellix® from preclinical development through the I, II and III phases, and on to registration and launch. Before that, he managed several other well-known projects through all phases. Jesper is also known for his excellence in stakeholder communications and is a member of consultancy group KLIFO.
With Jesper on board, our team now has all the skills required for the journey ahead. We are convinced that Jesper will make a strong contribution to the success of PN6047
Latest news
View all
Watch PharmNovo at LSX in Lisbon
Take the opportunity to listen to Per von Mentzer, CEO, presenting PN6047 at the LSX World Europe congress in Lisbon, March 2026. Learn how PharmNovo is shaping a new approach to pain relief with the goal to prove that powerful pain treatment doesn’t have to come with the cost of addiction. Discover how the company’s lead candidate PN6047, delivers effective pain relief without activating the mu-opioid receptor and avoiding the addiction risks associated with conventional opioids. The Phase II-ready Delta Opioid Receptor Agonist (DORA) with first-in-class potential, PN6047 represents a safer, non-addictive approach targeting a neuropathic pain market that is expected to double until 2033 and reach 13 bEUR.
Read more
Capsules ready for Phase IIa Study
PharmNovo is pleased to announce that that the company has completed drug product manufacturing for its lead candidate PN6047. This is an important milestone as the company prepares for its upcoming Phase IIa proof-of-concept study in neuropathic pain.
Read more
Welcome on Board
As the company prepares for the next phase of clinical development, the new Board composition strengthens our strategic capabilities ahead of Phase II development of our lead candidate, PN6047.
Read more
